Allison B Rosen
Affiliation: University of Michigan
- The value of coronary heart disease care for the elderly: 1987-2002Allison B Rosen
University of Michigan and Ann Arbor Veterans Affairs, USA
Health Aff (Millwood) 26:111-23. 2007..Overall, the value of our CHD spending is quite good. Despite this wise investment of resources to date, considerable opportunities remain for additional investment to improve the adoption of valuable but underused health services...
- Patient adherence: a blind spot in cost-effectiveness analyses?Allison B Rosen
Departments of Internal Medicine and Health Management and Policy, University of Michigan, 300 N Ingalls, Ste 7E10, Ann Arbor, MI 48109, USA
Am J Manag Care 15:626-32. 2009..Despite evidence that medication adherence can influence cost-effectiveness analysis (CEA) results, the extent to which published CEAs include adherence has not been fully characterized...
- Challenges in building disease-based national health accountsAllison B Rosen
Division of General Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan, USA
Med Care 47:S7-13. 2009..Measuring spending on diseases is critical to assessing the value of medical care...
- A controlled trial of value-based insurance design - the MHealthy: Focus on Diabetes (FOD) trialAlicen Spaulding
Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, MI, USA
Implement Sci 4:19. 2009..We describe the design and implementation of MHealthy: Focus on Diabetes (FOD), a prospective, controlled trial of targeted co-payment reductions for high value, underutilized therapies for individuals with diabetes...
- Quality of abstracts of papers reporting original cost-effectiveness analysesAllison B Rosen
Division of General Medicine, University of Michigan Health Systems, Department of Health Management and Policy, University of Michigan School of Public Health, Ann Arbor Veterans Affairs Medical Center, Ann Arbor, MI 48109, USA
Med Decis Making 25:424-8. 2005..The authors examined the extent to which abstracts of published CEAs include key data elements (intervention, comparator, target population, study perspective) and assessed the effect of journal characteristics on reporting quality...
- Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetesAllison B Rosen
Division of General Medicine, University of Michigan Health Systems, 300 North Ingalls, Suite 7E10, Ann Arbor, MI 48109, USA
Ann Intern Med 143:89-99. 2005..Angiotensin-converting enzyme (ACE) inhibitors slow renal disease progression and reduce cardiac morbidity and mortality in patients with diabetes. Patients' out-of-pocket costs pose a barrier to using this effective therapy...
- Physicians' views of interventions to reduce medical errors: does evidence of effectiveness matter?Allison B Rosen
Division of General Medicine, University of Michigan Health Systems, 300 North Ingalls, Suite 7C27, Ann Arbor, MI 48109, USA
Acad Med 80:189-92. 2005..It further assessed whether academic affiliation was associated with physicians' ratings of effectiveness...
- Indications for and utilization of ACE inhibitors in older individuals with diabetes. Findings from the National Health and Nutrition Examination Survey 1999 to 2002Allison B Rosen
Division of General Medicine, University of Michigan Health Systems, Ann Arbor, MI 48109, USA
J Gen Intern Med 21:315-9. 2006..Despite the marked benefit, it is unknown what percentage of patients with diabetes would benefit from and what percentage actually receive this preventive therapy...
- Hospitalizations and deaths among adults with cardiovascular disease who underuse medications because of cost: a longitudinal analysisMichele Heisler
Veterans Affairs Center for Clinical Practice Management Research, VA Ann Arbor Healthcare System, Ann Arbor, MI 48113 0170, USA
Med Care 48:87-94. 2010..Less is known about the extent to which such cost-related medication underuse is associated with increases in subsequent hospitalizations and deaths...
- Rising out-of-pocket costs in disease management programsMichael E Chernew
University of Michigan, Ann Arbor, MI 48109 2029, USA
Am J Manag Care 12:150-4. 2006..To document the rise in copayments for patients in disease management programs and to call attention to the inherent conflicts that exist between these 2 approaches to benefit design...
- Trends in the prevalence and mortality of cognitive impairment in the United States: is there evidence of a compression of cognitive morbidity?Kenneth M Langa
Division of General Medicine, Department of Medicine, University of Michigan, Ann Arbor, MI, USA
Alzheimers Dement 4:134-44. 2008..To assess the impact of these multiple trends, we compared the prevalence and 2-year mortality of cognitive impairment (CI) consistent with dementia in the United States in 1993 to 1995 and 2002 to 2004...
- Impact of decreasing copayments on medication adherence within a disease management environmentMichael E Chernew
Harvard Medical School, Boston, Massachusetts, USA
Health Aff (Millwood) 27:103-12. 2008..The results demonstrate the potential for copayment reductions for highly valued services to increase medication adherence above the effects of existing DM programs...
- Views of practicing physicians and the public on medical errorsRobert J Blendon
Department of Health Policy and Management, Harvard School of Public Health, Boston 02115, USA
N Engl J Med 347:1933-40. 2002..What is not known is the level of support for these proposed changes among practicing physicians and the public...
- Do drug formulary policies reflect evidence of value?Peter J Neumann
Department of Health Policy and Management and Center for Risk Analysis, Harvard School of Public Health, Boston, MA 02115, USA
Am J Manag Care 12:30-6. 2006..To investigate the extent to which preferred drug lists and tiered formularies reflect evidence of value, as measured in published cost-utility analyses (CUAs)...
- Medicare and cost-effectiveness analysisPeter J Neumann
Department of Health Policy and Management and the Center for Risk Analysis, Harvard School of Public Health, Boston, USA
N Engl J Med 353:1516-22. 2005
- Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high-risk clinical and ethnic groups with diabetesAllison B Rosen
Department of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts, USA
J Gen Intern Med 19:669-75. 2004..Angiotensin-converting enzyme inhibitors (ACE) and angiotensin receptor blockers (ARB) slow the progression of diabetic nephropathy, yet little is known about their use among patients at high risk for progression to ESRD...
- Growth and quality of the cost-utility literature, 1976-2001Peter J Neumann
Program on the Economic Evaluation of Medical Technology, Center for Risk Analysis, Harvard School of Public Health, Boston, MA 02115, USA
Value Health 8:3-9. 2005..This study updates and expands our previous work, which examined CUAs through 1997...
- Cost-utility analysis studies of depression management: a systematic reviewPaul A Pirraglia
Rhode Island Hospital, 593 Eddy St, MPB 1, Providence, RI 02903, USA
Am J Psychiatry 161:2155-62. 2004....
- Diffusion of published cost-utility analyses in the field of health policy and practiceSeema S Sonnad
Department of Surgery, University of Pennsylvania, Philadelphia, Pennsylvania 19104 4283, USA
Int J Technol Assess Health Care 21:399-402. 2005..The diffusion of cost-utility analyses (CUAs) through the medical literature was examined, documenting visible patterns and determining how they correspond with expectations about the diffusion of process innovations...
- Variations in risk attitude across race, gender, and educationAllison B Rosen
Department of Health Policy and Management, Harvard School of Public Health, Boston, MA, USA
Med Decis Making 23:511-7. 2003..Little is known about the patient-specific factors that may contribute to this variation. This study examined variations in risk attitude across major sociodemographic groups...
- Colorectal cancer screening disparities related to obesity and genderAllison B Rosen
Department of Health and Management, Harvard School of Public Health, Beth Israel Deaconess Medical Center, Brigham and Womens Hospital, Boston, Massachusetts 02215, USA
J Gen Intern Med 19:332-8. 2004..Obese women are less likely to undergo breast and cervical cancer screening than nonobese women. It is not known whether obesity is associated with a lower likelihood of colorectal cancer screening...
- Delays in publication of cost utility analyses conducted alongside clinical trials: registry analysisDan Greenberg
Harvard Center for Risk Analysis, Department of Health Policy and Management, Harvard School of Public Health, 718 Huntington Avenue, Boston, MA 02115, USA
BMJ 328:1536-7. 2004
- The impact of symptoms and impairments on overall health in US national health dataSusan T Stewart
Program for Health Systems Improvement, Harvard University, Cambridge, Massachusetts, USA
Med Care 46:954-62. 2008..To assess the effects on overall self-rated health of the broad range of symptoms and impairments that are routinely asked about in national surveys...
- Confronting hysteria: a reply to Fairman and CurtissMichael E Chernew
J Manag Care Pharm 14:324-6; author reply 326-8. 2008
- Linking cost sharing to value: an unrivaled yet unrealized public health opportunityR Scott Braithwaite
Yale University School of Medicine and Veterans Affairs Connecticut Healthcare System, New Haven, Connecticut 06516, USA
Ann Intern Med 146:602-5. 2007..Systematic efforts to discourage inappropriate cost sharing may improve public health...
- Value-based insurance designMichael E Chernew
Harvard University, Boston, Massachusetts, USA
Health Aff (Millwood) 26:w195-203. 2007..This paper makes the case for VBID and outlines current VBID initiatives in the private sector as well as barriers to further adoption...
- Trends in cost effectiveness analyses in orthopaedic surgeryCarmen A Brauer
Department of Orthopaedic Surgery, British Columbia Children s Hospital, Vancouver, BC, Canada
Clin Orthop Relat Res 457:42-8. 2007....
- The value of medical spending in the United States, 1960-2000David M Cutler
Department of Economics, Harvard University, and the National Bureau of Economic Research, Cambridge, Mass 02138, USA
N Engl J Med 355:920-7. 2006..The increased use of medical therapies has led to increased medical costs. To provide insight into the value of this increased spending, we compared gains in life expectancy with the increased costs of care from 1960 through 2000...
- Trends in the measurement of health utilities in published cost-utility analysesCarmen A Brauer
Harvard Center for Risk Analysis, Harvard School of Public Health, Boston, MA, USA
Value Health 9:213-8. 2006..tufts-nemc.org/cearegistry; previously at http://www.hsph.harvard.edu/cearegistry), and documents recent changes in methods used for utility weight elicitation...
- A synthesis of cost-utility analysis literature in infectious diseasePatricia W Stone
Columbia University School of Nursing, New York, NY 10032, USA
Lancet Infect Dis 5:383-91. 2005..The results of cost-utility analyses have important implications for the development of clinical guidelines and resource allocation decisions. More trained investigators and better peer-review processes are needed...
- Cost-utility analyses in orthopaedic surgeryCarmen A Brauer
Harvard Center for Risk Analysis, Harvard School of Public Health, 718 Huntington Avenue, Boston, MA 02115, USA
J Bone Joint Surg Am 87:1253-9. 2005..We critically reviewed the literature on orthopaedic cost-utility analysis to determine which subspecialty areas are represented, the cost-utility ratios that have been utilized, and the quality of the present literature...
- Can we better prioritize resources for cost-utility research?Peter J Neumann
Harvard School of Public Health, Boston, MA 02115, USA
Med Decis Making 25:429-36. 2005....
- Bias in published cost effectiveness studies: systematic reviewChaim M Bell
St Michael s Hospital, Toronto, Ontario, Canada M5B 1W8
BMJ 332:699-703. 2006....